JP2020529410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529410A5 JP2020529410A5 JP2020505208A JP2020505208A JP2020529410A5 JP 2020529410 A5 JP2020529410 A5 JP 2020529410A5 JP 2020505208 A JP2020505208 A JP 2020505208A JP 2020505208 A JP2020505208 A JP 2020505208A JP 2020529410 A5 JP2020529410 A5 JP 2020529410A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023075458A JP2023106433A (ja) | 2017-07-31 | 2023-05-01 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
| JP2025092507A JP2025131681A (ja) | 2017-07-31 | 2025-06-03 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539421P | 2017-07-31 | 2017-07-31 | |
| US62/539,421 | 2017-07-31 | ||
| PCT/US2018/044610 WO2019028027A1 (en) | 2017-07-31 | 2018-07-31 | PROTEINS BINDING TO NKG2D, CD16 AND FLT3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023075458A Division JP2023106433A (ja) | 2017-07-31 | 2023-05-01 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529410A JP2020529410A (ja) | 2020-10-08 |
| JP2020529410A5 true JP2020529410A5 (enExample) | 2021-09-24 |
Family
ID=65233032
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505208A Pending JP2020529410A (ja) | 2017-07-31 | 2018-07-31 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
| JP2023075458A Pending JP2023106433A (ja) | 2017-07-31 | 2023-05-01 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
| JP2025092507A Pending JP2025131681A (ja) | 2017-07-31 | 2025-06-03 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023075458A Pending JP2023106433A (ja) | 2017-07-31 | 2023-05-01 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
| JP2025092507A Pending JP2025131681A (ja) | 2017-07-31 | 2025-06-03 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200165344A1 (enExample) |
| EP (1) | EP3661554A4 (enExample) |
| JP (3) | JP2020529410A (enExample) |
| KR (2) | KR20250051800A (enExample) |
| CN (1) | CN111132698A (enExample) |
| AU (2) | AU2018309712A1 (enExample) |
| BR (1) | BR112020001972A2 (enExample) |
| CA (1) | CA3070986A1 (enExample) |
| CO (1) | CO2020001981A2 (enExample) |
| EA (1) | EA202090387A1 (enExample) |
| IL (1) | IL272374A (enExample) |
| MA (1) | MA49769A (enExample) |
| MX (1) | MX2020001257A (enExample) |
| SG (1) | SG11202000632QA (enExample) |
| WO (1) | WO2019028027A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4491234A3 (en) | 2017-02-08 | 2025-04-09 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| BR112019017197A2 (pt) | 2017-02-20 | 2020-04-14 | Dragonfly Therapeutics, Inc. | proteínas que se ligam a her2, nkg2d e cd16 |
| AU2019218125B2 (en) | 2018-02-08 | 2025-03-13 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
| TW201942134A (zh) | 2018-02-20 | 2019-11-01 | 美商蜻蜓醫療公司 | 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法 |
| JOP20200234A1 (ar) | 2018-03-27 | 2020-09-15 | Xyphos Biosciences Inc | نطاقات a1-a2 معدلة لمركبات ترابطية nkg2d غير طبيعية ترتبط بمستقبلات nkg2d غير طبيعية. |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| AU2019404098A1 (en) | 2018-12-18 | 2021-05-27 | Boehringer Ingelheim Io Canada Inc. | FLT3 agonist antibodies and uses thereof |
| AR120223A1 (es) * | 2019-10-15 | 2022-02-02 | Dragonfly Therapeutics Inc | Proteínas que unen nkg2d, cd16 y flt3 |
| IL295448A (en) * | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
| EP4146271A4 (en) | 2020-05-06 | 2024-09-04 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A |
| US12377144B2 (en) | 2021-03-03 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen |
| CN117580865A (zh) * | 2021-06-29 | 2024-02-20 | 山东先声生物制药有限公司 | Cd16抗体及其应用 |
| WO2026052582A1 (en) | 2024-09-04 | 2026-03-12 | Red Ridge Bio Ag | Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5591712B2 (ja) * | 2007-12-14 | 2014-09-17 | ノボ・ノルデイスク・エー／エス | ヒトｎｋｇ２ｄに対する抗体とその使用 |
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| JP5944831B2 (ja) * | 2009-12-23 | 2016-07-05 | シュニムネ ゲーエムベーハーＳＹＮＩＭＭＵＮＥ ＧｍｂＨ | 抗ｆｌｔ３抗体及びその使用方法 |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2794658B1 (en) * | 2011-12-19 | 2017-03-15 | Synimmune GmbH | Bispecific antibody molecule |
| JP6628966B2 (ja) * | 2012-06-14 | 2020-01-15 | 中外製薬株式会社 | 改変されたＦｃ領域を含む抗原結合分子 |
| DK3126384T3 (da) * | 2014-04-01 | 2021-01-18 | Adimab Llc | Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse |
| WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
-
2018
- 2018-07-31 MX MX2020001257A patent/MX2020001257A/es unknown
- 2018-07-31 KR KR1020257011280A patent/KR20250051800A/ko active Pending
- 2018-07-31 WO PCT/US2018/044610 patent/WO2019028027A1/en not_active Ceased
- 2018-07-31 EA EA202090387A patent/EA202090387A1/ru unknown
- 2018-07-31 EP EP18840650.8A patent/EP3661554A4/en active Pending
- 2018-07-31 AU AU2018309712A patent/AU2018309712A1/en not_active Abandoned
- 2018-07-31 CA CA3070986A patent/CA3070986A1/en active Pending
- 2018-07-31 KR KR1020207005238A patent/KR20200033302A/ko not_active Ceased
- 2018-07-31 SG SG11202000632QA patent/SG11202000632QA/en unknown
- 2018-07-31 MA MA049769A patent/MA49769A/fr unknown
- 2018-07-31 JP JP2020505208A patent/JP2020529410A/ja active Pending
- 2018-07-31 US US16/635,079 patent/US20200165344A1/en not_active Abandoned
- 2018-07-31 BR BR112020001972-0A patent/BR112020001972A2/pt not_active Application Discontinuation
- 2018-07-31 CN CN201880062880.1A patent/CN111132698A/zh active Pending
-
2020
- 2020-01-30 IL IL272374A patent/IL272374A/en unknown
- 2020-02-25 CO CONC2020/0001981A patent/CO2020001981A2/es unknown
-
2023
- 2023-05-01 JP JP2023075458A patent/JP2023106433A/ja active Pending
-
2025
- 2025-06-03 JP JP2025092507A patent/JP2025131681A/ja active Pending
- 2025-06-19 AU AU2025204591A patent/AU2025204591A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529410A5 (enExample) | ||
| JP2023106433A5 (enExample) | ||
| JP2021098732A5 (enExample) | ||
| Krah et al. | Engineering bispecific antibodies with defined chain pairing | |
| JP2023052214A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020507328A5 (enExample) | ||
| JP2019023184A5 (enExample) | ||
| JP2020510646A5 (enExample) | ||
| JP2020508997A5 (enExample) | ||
| JP2020521448A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| JP2020507577A5 (enExample) | ||
| JP2020531525A5 (enExample) | ||
| CA3232364A1 (en) | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof | |
| CN106397598B (zh) | 多价多特异性抗体及免疫杂合蛋白的表达和制备方法 | |
| RU2015145719A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| RU2020111554A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| CN104822704A (zh) | 针对分化簇3(cd3)的人源化的抗体 | |
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 | |
| WO2019196309A1 (zh) | 抗pd-l1抗体及其用途 | |
| JPWO2020033587A5 (enExample) | ||
| JPWO2020146221A5 (enExample) | ||
| Acheampong | Bispecific antibody (bsAb) construct formats and their application in cancer therapy | |
| JPWO2021076564A5 (enExample) |